ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for the MULTIDISCIPLINARY CANCER CARE TEAM and the PATIENTS THEY SERVE since 1993
Meetings & Education
Financial Advocacy & Patient Assistance
NCOA Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Off-Label Use Literature
Find A Clinical Trial
National Professional Organizations
Hurricane Florence Relief
NCOA Corporate Members
Become a Corporate Member
Industry News Archive
FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
On November 14, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
FDA granted this application priority review and zanubrutinib received orphan product and breakthrough therapy designations for treatment of MCL.
Read FDA announcement
Tweets by OSSatACCC